JP2005504789A5 - - Google Patents

Download PDF

Info

Publication number
JP2005504789A5
JP2005504789A5 JP2003526403A JP2003526403A JP2005504789A5 JP 2005504789 A5 JP2005504789 A5 JP 2005504789A5 JP 2003526403 A JP2003526403 A JP 2003526403A JP 2003526403 A JP2003526403 A JP 2003526403A JP 2005504789 A5 JP2005504789 A5 JP 2005504789A5
Authority
JP
Japan
Prior art keywords
substituted
group
alkyl
unsubstituted
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003526403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005504789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/027514 external-priority patent/WO2003022274A2/en
Publication of JP2005504789A publication Critical patent/JP2005504789A/ja
Publication of JP2005504789A5 publication Critical patent/JP2005504789A5/ja
Pending legal-status Critical Current

Links

JP2003526403A 2001-09-13 2002-08-28 癌治療のための２−アロイルイミダゾール化合物 Pending JP2005504789A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32210501P 2001-09-13 2001-09-13
PCT/US2002/027514 WO2003022274A2 (en) 2001-09-13 2002-08-28 2-aroylimidazole compounds for treating cancer

Publications (2)

Publication Number Publication Date
JP2005504789A JP2005504789A (ja) 2005-02-17
JP2005504789A5 true JP2005504789A5 (OSRAM) 2006-01-05

Family

ID=23253436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003526403A Pending JP2005504789A (ja) 2001-09-13 2002-08-28 癌治療のための２−アロイルイミダゾール化合物

Country Status (6)

Country Link
US (2) US6743919B2 (OSRAM)
EP (1) EP1427413A2 (OSRAM)
JP (1) JP2005504789A (OSRAM)
AU (1) AU2002323475B2 (OSRAM)
CA (1) CA2460345A1 (OSRAM)
WO (1) WO2003022274A2 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504789A (ja) * 2001-09-13 2005-02-17 シンタ ファーマスーティカルズ コーポレイション 癌治療のための２−アロイルイミダゾール化合物
AU2003209130B2 (en) * 2002-02-12 2008-06-05 Wisconsin Alumni Research Foundation Synthesis of indole thiazole compounds as ligands for the AH receptor
TW200503738A (en) * 2003-07-16 2005-02-01 Tzu Chi Buddhist General Hospital Method for extracting antineoplastic components from bupleurum scorzonerifolium
JP2007506763A (ja) * 2003-09-24 2007-03-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なイミダゾール組成物
JP4760712B2 (ja) * 2003-10-31 2011-08-31 オークランド ユニサーヴィスィズ リミテッド 新規ニトロフェニルマスタードおよびニトロフェニルアジリジンアルコールおよびそれらの対応するリン酸エステルおよびターゲットが決められた細胞毒性剤としてのそれらの使用
GB0403781D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical compounds
AR051090A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AR051093A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
AU2006279929A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
CA2631082C (en) * 2005-11-23 2015-02-03 Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
US7960544B2 (en) * 2005-12-16 2011-06-14 Ironwood Pharmaceuticals, Inc. Useful indole compounds
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US7501438B2 (en) 2006-07-07 2009-03-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
US20090325936A1 (en) * 2006-12-20 2009-12-31 Bilodeau Mark T Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
CA2703138A1 (en) * 2007-10-26 2009-04-30 F. Hoffmann-La Roche Ag Purine derivatives useful as pi3 kinase inhibitors
US8158624B2 (en) * 2008-05-30 2012-04-17 Genetech, Inc. Purine PI3K inhibitor compounds and methods of use
WO2010005558A2 (en) * 2008-07-07 2010-01-14 Xcovery, Inc. Pi3k isoform selective inhibitors
CA2761445A1 (en) 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
CN103003279B (zh) 2010-07-14 2015-09-23 弗·哈夫曼-拉罗切有限公司 对PI3K P110δ具有选择性的嘌呤化合物及其使用方法
JP2013536200A (ja) 2010-08-20 2013-09-19 アミラ ファーマシューティカルス，インコーポレーテッド オートタキシン阻害剤およびその使用
EP3053925A1 (en) 2010-12-16 2016-08-10 F. Hoffmann-La Roche AG Tricyclic pi3k inhibitor compounds and methods of use
EP2714680B1 (en) * 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN108841778B (zh) * 2018-04-28 2022-05-17 大连普瑞康生物技术有限公司 一种红豆杉细胞组织培养物
US12404265B2 (en) 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
EP4214197A1 (en) 2020-09-16 2023-07-26 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
AU2022320699A1 (en) 2021-07-28 2024-02-29 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
WO2023064486A1 (en) * 2021-10-14 2023-04-20 Galileo Biosystems, Inc. Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272810A3 (en) * 1986-11-26 1988-07-20 Harbor Branch Oceanographic Institution, Inc. Antitumor and antiviral alkaloids
US4866084A (en) * 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
US5290777A (en) 1993-02-24 1994-03-01 Regents Of The Univ. Of California Use for topsentin compounds and pharmaceutical compositions containing same
WO1997012862A1 (en) * 1995-10-03 1997-04-10 The Scripps Research Institute Cbi analogs of cc-1065 and the duocarmycins
US5955462A (en) 1996-10-31 1999-09-21 Harbor Branch Oceanographic Institution, Inc. Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
US6291501B1 (en) 1998-02-20 2001-09-18 Harbor Branch Oceanographic Institution, Inc. Compounds and methods of use for treatment of neurogenic inflammation
EP1093455B1 (en) 1998-07-08 2004-09-22 Harbor Branch Oceanographic Institution, Inc. Bis-indole derivatives and their use as antiinflammatory agents
AU772295B2 (en) * 1999-05-21 2004-04-22 Scios Inc. Indole-type derivatives as inhibitors of p38 kinase
JP2005504789A (ja) 2001-09-13 2005-02-17 シンタ ファーマスーティカルズ コーポレイション 癌治療のための２−アロイルイミダゾール化合物

Similar Documents

Publication Publication Date Title
JP2005504789A5 (OSRAM)
ES2569660T3 (es) Inhibidores de la IRE-1alfa
TW536539B (en) Novel substituted imidazole compounds
RU2008136187A (ru) Новое производное кумарина, обладающее противоопухолевой активностью
RU2017121906A (ru) Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии
JP2007504160A5 (OSRAM)
JP2001526220A5 (OSRAM)
JP2007504284A5 (OSRAM)
US8653276B2 (en) 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin II receptor antagonists
JP2007528417A5 (OSRAM)
JP2004509113A5 (OSRAM)
RU2006109108A (ru) Соединения, обладающие активностью антагонистов crth2 рецепторов
BG64507B1 (bg) Производни на карбамида като инхибитори на ензим инозин-5'-монофосфат дехидрогеназа
RU2003133448A (ru) 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс- хемокинового рецептора
JP2009534404A5 (OSRAM)
JP2007532651A5 (OSRAM)
RU2005119633A (ru) Антивирусные нуклеозидные производные
RU2012118667A (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
JP2006508970A5 (OSRAM)
KR20120055571A (ko) 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸
PT1689726E (pt) Derivados de 5-(benz-(z)-ilideno)-tiazolidin-4-ona como agentes imunossupressores
AU2011251622A1 (en) Lipoic acid and nitroxide derivatives and uses thereof
JPWO2019126691A5 (OSRAM)
JP2006507355A5 (OSRAM)
JP2006508147A5 (OSRAM)